The stock of Autolus Therapeutics plc ADR (AUTL) has gone down by -2.22% for the week, with a 11.86% rise in the past month and a -37.14% drop in the past quarter. The volatility ratio for the week is 8.36%, and the volatility levels for the past 30 days are 11.36% for AUTL. The simple moving average for the past 20 days is -2.83% for AUTL’s stock, with a -53.69% simple moving average for the past 200 days.
Is It Worth Investing in Autolus Therapeutics plc ADR (NASDAQ: AUTL) Right Now?
Moreover, the 36-month beta value for AUTL is 1.69. Analysts have varying opinions on the stock, with 8 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AUTL is 240.32M and currently, short sellers hold a 4.76% of that float. On May 08, 2025, AUTL’s average trading volume was 1.70M shares.
AUTL) stock’s latest price update
The stock of Autolus Therapeutics plc ADR (NASDAQ: AUTL) has increased by 7.32 when compared to last closing price of 1.23.Despite this, the company has seen a loss of -2.22% in its stock price over the last five trading days. globenewswire.com reported 2025-05-08 that Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 million U.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL) Encouraging preliminary data reported in Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE); planned Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in progressive forms of multiple sclerosis (MS) initiating before year-end 2025 Conference call to be held today at 08:30 am EDT/13:30 pm GMT: conference call participants should pre-register using the link at the bottom of this press release LONDON, May 08, 2025 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces its operational and financial results for the first quarter ended March 31, 2025. “We had a great first quarter of launch and are highly encouraged by physician enthusiasm for AUCATZYL in the U.S. We believe this speaks to the product profile and significant unmet need for patients,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
Analysts’ Opinion of AUTL
Many brokerage firms have already submitted their reports for AUTL stocks, with Goldman repeating the rating for AUTL by listing it as a “Buy.” The predicted price for AUTL in the upcoming period, according to Goldman is $7.60 based on the research report published on November 18, 2024 of the previous year 2024.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see AUTL reach a price target of $13. The rating they have provided for AUTL stocks is “Buy” according to the report published on November 15th, 2024.
Deutsche Bank gave a rating of “Buy” to AUTL, setting the target price at $10 in the report published on November 09th of the previous year.
AUTL Trading at -15.66% from the 50-Day Moving Average
After a stumble in the market that brought AUTL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.60% of loss for the given period.
Volatility was left at 11.36%, however, over the last 30 days, the volatility rate increased by 8.36%, as shares surge +9.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.47% lower at present.
During the last 5 trading sessions, AUTL fell by -2.22%, which changed the moving average for the period of 200-days by -69.30% in comparison to the 20-day moving average, which settled at $1.3585. In addition, Autolus Therapeutics plc ADR saw -43.83% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AUTL starting from Martin Pule, who proposed sale 698,741 shares at the price of $4.23 back on Sep 16 ’24. After this action, Martin Pule now owns shares of Autolus Therapeutics plc ADR, valued at $2,955,674 using the latest closing price.
Stock Fundamentals for AUTL
Current profitability levels for the company are sitting at:
- -22.73 for the present operating margin
- -0.72 for the gross margin
The net margin for Autolus Therapeutics plc ADR stands at -21.8. The total capital return value is set at -0.32. Equity return is now at value -81.91, with -38.11 for asset returns.
Based on Autolus Therapeutics plc ADR (AUTL), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -3.92. The debt to equity ratio resting at 0.12. The interest coverage ratio of the stock is -24.75.
Currently, EBITDA for the company is -182.42 million with net debt to EBITDA at 0.86. When we switch over and look at the enterprise to sales, we see a ratio of 17.94. The receivables turnover for the company is 0.21for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.84.
Conclusion
To wrap up, the performance of Autolus Therapeutics plc ADR (AUTL) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
